Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Busch, Jonas ^a   Ralla, Bernhard ^a   Jung, Monika ^a   Wotschofsky, Zofia ^a,b   Trujillo Arribas, Elena ^c   Schwabe, Philipp ^a   Kilic, Ergin ^a   Fendler, Annika ^a,b,d   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute of Urologic Research   (Germany)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Clear cell renal cell carcinoma; Metastasis; Overall survival; piRNA; Prognosis; Recurrence

Indexed keywords

PIWI INTERACTING RNA; PIWI INTERACTING RNA 30924; PIWI INTERACTING RNA 38756; PIWI INTERACTING RNA 57125; UNCLASSIFIED DRUG; ARGONAUTE PROTEIN; PIWIL1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER PROGNOSIS; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NEPHRECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR RECURRENCE; GENETICS; METABOLISM; METASTASIS; MORTALITY; PROGNOSIS; SURVIVAL ANALYSIS;

ARGONAUTE PROTEINS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; PROGNOSIS; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS;

EID: 84931291844     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0180-3     Document Type: Article

References (50)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-86.
2. Stewart GD, O'Mahony FC, Powles T, Riddick AC, Harrison DJ, Faratian D. What can molecular pathology contribute to the management of renal cell carcinoma? Nat Rev Urol. 2011;8:255-65.
3. Ljungberg, B, Bensalah, K, Bex, A, et al. Systematic Review Methodology for the European Association of Urology Guidelines for Renal Cell Carcinoma (2014 update). http://www.uroweb.org/gls/refs/Systematic-methodology-RCC-2014-update.pdf. Accessed 5 May, 2015.
4. Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490-504.
5. Hattab EA, Cheng L, Eble JN. Neoplasms of the Kidney. In: Zhou M, Magi-Galluzzi C, editors. Genitourinary Pathology. Philadelphia: Churchill Livingstone/Elsevier; 2007. p. 281-340.
6. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763-71.
7. Steffens S, Janssen M, Roos FC, et al. Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma-a multicentre study. Eur J Cancer. 2012;48:2347-52.
8. Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology. 2007;69:230-5.
9. Howlader, N, Noone, AM, Krapcho, M, et al. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1975-2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014. Accessed 5 May, 2015.
10. Tan PH, Cheng L, Rioux-Leclercq N, et al. Renal tumors: diagnostic and prognostic biomarkers. Am J Surg Pathol. 2013;37:1518-31.
11. Sun M, Shariat SF, Cheng C, et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011;60:644-61.
12. Butz H, Szabo PM, Nofech-Mozes R, et al. Integrative bioinformatics analysis reveals new prognostic biomarkers of clear cell renal cell carcinoma. Clin Chem. 2014;60:1314-26.
13. Schaefer A, Stephan C, Busch J, Yousef GM, Jung K. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol. 2010;7:286-97.
14. Thomson T, Lin H. The biogenesis and function of PIWI proteins and piRNAs: progress and prospect. Annu Rev Cell Dev Biol. 2009;25:355-76.
15. Girard A, Sachidanandam R, Hannon GJ, Carmell MA. A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature. 2006;442:199-202.
16. Aravin A, Gaidatzis D, Pfeffer S, et al. A novel class of small RNAs bind to MILI protein in mouse testes. Nature. 2006;442:203-7.
17. Sai Lakshmi S, Agrawal S. piRNABank: a web resource on classified and clustered Piwi-interacting RNAs. Nucleic Acids Res. 2008;36:D173-7.
18. Zhang P, Si X, Skogerbo G, et al. piRBase: a web resource assisting piRNA functional study. Database (Oxford). 2014;2014:bau110.
19. Cui L, Lou Y, Zhang X, et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using piRNAs as markers. Clin Biochem. 2011;44:1050-7.
20. Cheng J, Guo JM, Xiao BX, et al. piRNA, the new non-coding RNA, is aberrantly expressed in human cancer cells. Clin Chim Acta. 2011;412:1621-5.
21. Siddiqi S, Matushansky I. Piwis and piwi-interacting RNAs in the epigenetics of cancer. J Cell Biochem. 2012;113:373-80.
22. Huang G, Hu H, Xue X, et al. Altered expression of piRNAs and their relation with clinicopathologic features of breast cancer. Clin Transl Oncol. 2013;15:563-8.
23. Zhang H, Ren Y, Xu H, Pang D, Duan C, Liu C. The expression of stem cell protein Piwil2 and piR-932 in breast cancer. Surg Oncol. 2013;22:217-23.
24. Mei Y, Clark D, Mao L. Novel dimensions of piRNAs in cancer. Cancer Lett. 2013;336:46-52.
25. Chu H, Hui G, Yuan L, et al. Identification of novel piRNAs in bladder cancer. Cancer Lett. 2015;356:561-7.
26. Trpkov K, Grignon DJ, Bonsib SM, et al. Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. Am J Surg Pathol. 2013;37:1505-17.
27. Santoni M, Conti A, Procopio G, et al. Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis? J Exp Clin Cancer Res. 2015;34:10.
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93:387-91.
29. Srigley JR, Amin MB, Delahunt B, et al. Protocol for the examination of specimens from patients with invasive carcinoma of renal tubular origin. Arch Pathol Lab Med. 2010;134:e25-30.
30. Wotschofsky Z, Meyer HA, Jung M, et al. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. Anal Biochem. 2011;417:233-41.
31. Wotschofsky Z, Liep J, Meyer H-A, et al. Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int J Biol Sci. 2012;8:1363-74.
32. Chai H, Brown RE. Field effect in cancer - an update. Ann Clin Lab Sci. 2009;39:331-7.
33. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002.
34. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-63.
35. Jung M, Mollenkopf HJ, Grimm C, et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med. 2009;13:3918-28.
36. Jung M, Schaefer A, Steiner I, et al. Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. Clin Chem. 2010;56:998-1006.
37. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611-22.
38. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
39. Littman BH, Di ML, Plebani M, Marincola FM. What's next in translational medicine? Clin Sci (Lond). 2007;112:217-27.
40. Wang Y, Barbacioru C, Hyland F, et al. Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics. 2006;7:59.
41. Ach RA, Wang H, Curry B. Measuring microRNAs: comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods. BMC Biotechnol. 2008;8:69.
42. Fendler A, Stephan C, Yousef GM, Jung K. MicroRNAs as regulators of signal transduction in urological tumors. Clin Chem. 2011;57:954-68.
43. Wotschofsky Z, Busch J, Jung M, et al. Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clin Chim Acta. 2013;416:5-10.
44. Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature. 2008;451:949-52.
45. Esposito T, Magliocca S, Formicola D, Gianfrancesco F. piR-015520 belongs to Piwi-associated RNAs regulates expression of the human melatonin receptor 1A gene. PLoS One. 2011;6:e22727.
46. The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43-9.
47. Wang K, Liang C, Liu J, et al. Prediction of piRNAs using transposon interaction and a support vector machine. BMC Bioinformatics. 2014;15:419.
48. Belinky F, Bahir I, Stelzer G, et al. Non-redundant compendium of human ncRNA genes in GeneCards. Bioinformatics. 2013;29:255-61.
49. Weick EM, Miska EA. piRNAs: from biogenesis to function. Development. 2014;141:3458-71.
50. Liu X, Chen X, Yu X, et al. Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res. 2013;32:96.